Related Experiment Video
Updated: Jan 3, 2026
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Diagnostic performance for declined microRNA-133a in pancreatic cancer
1First Department of General Surgery, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Abstract:
MicroRNA-133a (MiR-133a) is proven to exhibit a decreasing tendency in several cancers, as well as pancreatic cancer. Through the present study, we inspected performance for serum miR-133a in diagnosing pancreatic cancer. Serum samples were collected from 110 pancreatic cancer and 64 healthy persons. Relative messenger RNA level for miR-133a in serum specimens was gauged adopting quantitative real-time polymerase chain reaction (qRT-PCR), and compared betwixt two groups employing the Student t test. Receiver operating characteristics (ROC) analysis evaluated miR-133a performance in diagnosing pancreatic cancer. MiR-133a displayed a declining trend among pancreatic cancer samples, compared to the healthy controls (P < .001). The reduced miR-133a degree held strong relation to tumor dimension (P = .002), vessel invasion (P = .004), tumor lymph node metastasis stage (P = .002), and lymph node metastasis (P < .001). In addition, ROC analysis demonstrated that the area under the curve value was 0.893, accompanied by a sensitivity of 90.6% and a specificity of 87.2%, revealing fine execution for serum miR-133a in diagnosing cancer. The downregulation of miR-133a might possess a tight relation to hostile advancement in pancreatic cancer. Serum miR-133a could function as a potential diagnostic indicator for pancreatic cancer.
Insights
Serum microRNA-133a (miR-133a) is significantly decreased in pancreatic cancer patients. This finding suggests serum miR-133a is a promising biomarker for diagnosing pancreatic cancer and understanding its progression.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- MicroRNA-133a (miR-133a) levels are often reduced in various cancers, including pancreatic cancer.
- Investigating serum miR-133a can offer insights into pancreatic cancer diagnosis.
Purpose of the Study:
- To evaluate the diagnostic performance of serum miR-133a in distinguishing pancreatic cancer patients from healthy individuals.
- To explore the correlation between serum miR-133a levels and clinicopathological features of pancreatic cancer.
Main Methods:
- Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure serum miR-133a levels in 110 pancreatic cancer patients and 64 healthy controls.
- Statistical analysis, including Student t test and Receiver Operating Characteristic (ROC) analysis, was employed.
- Correlations with tumor dimension, vessel invasion, and lymph node metastasis were assessed.
Main Results:
- Serum miR-133a levels were significantly lower in pancreatic cancer patients compared to healthy controls (P < .001).
- Reduced miR-133a levels correlated with larger tumor size, vessel invasion, and advanced lymph node metastasis (P ≤ .004).
- ROC analysis showed an area under the curve of 0.893, with 90.6% sensitivity and 87.2% specificity.
Conclusions:
- Downregulation of miR-133a is associated with aggressive progression in pancreatic cancer.
- Serum miR-133a demonstrates potential as a non-invasive diagnostic biomarker for pancreatic cancer.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs